Amyloidosis Market Summary
DelveInsight’s “Amyloidosis Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Amyloidosis, along with historical and forecasted epidemiology and the Amyloidosis therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036 segmented by the seven major markets. It also covers the current Amyloidosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the Amyloidosis market. According to DelveInsight, the Amyloidosis market in the 7MM is expected to witness a major change during the study period 2022–2036.
Explore DelveInsight’s Full Coverage on the Amyloidosis Market
Amyloidosis Overview
Amyloidosis is a rare group of disorders caused by the abnormal buildup of amyloid proteins in tissues and organs, impairing their normal function. It can affect the heart, kidneys, liver, nerves, and gastrointestinal tract, leading to symptoms that vary depending on the organs involved. Major types include AL (light-chain), ATTR (transthyretin), and AA amyloidosis, each requiring distinct treatment approaches. Advances in diagnostic techniques, targeted therapies, and increased disease awareness are improving patient outcomes. Ongoing research focuses on early detection, novel disease-modifying treatments, and personalized care strategies, driving progress in the management of this complex and potentially life-threatening condition.
Explore DelveInsight’s Comprehensive Insights on the Amyloidosis Market
Amyloidosis Diagnosis and Treatment Algorithm
Amyloidosis diagnosis requires a systematic approach to identify the specific amyloid protein, determine the extent of organ involvement, and guide appropriate therapy. The diagnostic process typically includes clinical evaluation, laboratory tests, imaging studies, tissue biopsy with Congo red staining, and advanced techniques such as mass spectrometry or immunohistochemistry for accurate amyloid typing. Treatment algorithms are tailored according to the amyloidosis subtype, including AL, ATTR, or AA amyloidosis. Management may involve chemotherapy, targeted therapies, transthyretin stabilizers, gene-silencing agents, supportive care, and, in selected cases, stem cell or organ transplantation. Early diagnosis and personalized treatment significantly improve patient outcomes and quality of life.
Amyloidosis Epidemiology
The epidemiology section provides insights about the historical and current Amyloidosis patient pool and forecasted trends for each of the seven major countries. It helps identify the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with the assumptions undertaken.
Key Findings:
- The disease epidemiology covered in the report provides the historical as well as forecasted Amyloidosis epidemiology scenario in the 7MM, covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036
- The epidemiology segment also provides Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
Amyloidosis Recent Developments
- In March 2025, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that WAINZUA (eplontersen), developed in collaboration with AstraZeneca, had been approved in the European Union for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR-PN or ATTRv-PN) in adult patients with stage 1 or stage 2 polyneuropathy. WAINZUA is the only approved treatment in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.
Amyloidosis Drug Chapters
The drug chapter segment encloses a detailed analysis of Amyloidosis marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps in understanding the Amyloidosis clinical trial details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Amyloidosis Market Drivers
- Rising prevalence of amyloidosis
- Advancements in diagnostic technologies
- Growing awareness and early diagnosis
- Expanding pipeline of novel therapies
- Increased investment in rare disease research
Amyloidosis Market Barriers
- Amyloidosis Market Challenges
- Amyloidosis Market Obstacles
- Amyloidosis Market Limitations
- Amyloidosis Market Hurdles
- Amyloidosis Market Restraints
Amyloidosis Market Outlook
The market outlook segment of the report helps build a detailed comprehension of the historic, current, and forecasted Amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and the view of key opinion leaders. The calculated Amyloidosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Amyloidosis market in the 7MM is expected to witness a major change in the study period 2022–2036.
Download the Amyloidosis market report for in-depth insights on pipeline and forecast
Conclusion
The Amyloidosis market is positioned for continued evolution through 2036, shaped by ongoing epidemiological assessment across the seven major markets and a treatment landscape that continues to advance. Recent regulatory milestones, such as the EU approval of WAINZUA (eplontersen) for hereditary transthyretin-mediated amyloidosis, reflect the incremental progress being made in expanding self-administered treatment options for patients. As diagnostic practices, treatment algorithms, and the emerging pipeline continue to develop across the US, EU5, and Japan, the Amyloidosis market is expected to undergo meaningful transformation, presenting new opportunities for stakeholders while addressing the unmet needs associated with this condition.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
